The Weekly Roundup: March 30-April 3

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Top 5 Articles of the Month: March 2026

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

The Aesthetic Edge: March 2026

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of March

Interview Intersection: Expert Interviews From March 2026

Dermatology Times is recapping our exclusive expert interviews from the month of March.

Dermatology Times March 2026 Print Recap

Learn more about the in-depth topics covered in the March 2026 print issue of Dermatology Times.

Applying Clinical Trial Data to Alopecia Areata Treatment

Experts discuss how clinicians translate clinical trial results into practical treatment decisions for alopecia areata.

IL-17 vs IL-23: Insights from the BE BOLD PsA Trial

The trial’s results may support earlier use of dual IL-17A/F inhibitors in patients with both skin and joint disease.

Dermatology Times March 2026 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of March.

Amlitelimab Meets Primary Endpoints in 2 of 3 Phase 3 AD Trials

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

Almirall Announces Expanded CVS Caremark Coverage and New Clinical Data for Tirbanibulin at AAD 2026

Christopher Bunick, MD, PhD, and Almirall's Johnny Im discuss new data showing that tirbanibulin 1% ointment provides consistent efficacy, while expanded coverage is poised to improve patient care.

85% of Biologic-Eligible AD Patients Left Behind — Can KT-621 Reach Them?

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

Phase 2b/3 Study Begins for LPP With Brepocitinib

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

Novel Topical Therapy Offers New Path Forward for Oncology-Related Dermatologic Care

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

Dermatology Times Conferences & Meetings Calendar: April 2026

Explore top dermatology conferences and meetings in April 2026 and let us know which ones you'll be attending!

Inside the Mind of NP and PA Candidates: What Employers Often Miss

Offers must pair strong compensation with operational and cultural support to succeed.

Henry W. Lim, MD, FAAD, Awarded AAD Gold Medal for Lifetime Contributions to Global Dermatology

AAD honors Henry W. Lim, MD, FAAD, with the Academy's highest honor for his work in photodermatology advances, skin of color care, and global leadership.

Skin & Psych: APMNA Meeting Draws Record Interest as Psycho-Derm Gains Momentum

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic diseases.

How EVO301’s Unique IL-18 Binding Mechanism and Phase 2a Results Could Target Unmet Needs in AD

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the horizon.

Reputation Management and the Dermatologist's Role in Social Media

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.